Study of Magnesium Sulphate Injection for Pain Control After Gallbladder Surgery

A prospective randomized controlled study to assess the Effect of Intravenous Injection of Magnesium Sulphate 30 mg per kg on Intraoperative End-Tidal Carbon Dioxide Level and Postoperative Pain in patients undergoing Laparoscopic Cholecystectomy - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099730

Enrollment

Registered

2025-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R52- Pain, unspecified

Interventions

Intervention1: Magnesium Sulphate 30 mg per kg intravenous: Given preoperatively before induction for over 10 minutes Control Intervention1: Normal saline intravenous: Equal volume given over 10 minut

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients of both genders aged between 18 to 65 years Patients Scheduled for elective laparoscopic cholecystectomy under general anesthesia American Society of Anesthesiologists physical status I or II Patients who provide written informed consent

Exclusion criteria

Exclusion criteria: Age 18 and 65 years Patient not giving written consent for study participation. ASA physical status III and IV Known allergy or hypersensitivity to magnesium sulfate History of renal impairment or dysfunction eg creatinine clearance less than 60 ml per min Patients with cardiac conduction abnormalities eg heart block Patients on calcium channel blockers or magnesium-containing medications Severe hepatic dysfunction

Design outcomes

Primary

Measure	Time frame
To assess the changes in intraoperative EtCO2 following administration of intravenous magnesium sulphate. To evaluate the effect of magnesium sulphate on postoperative pain scoresTimepoint: To assess the changes in intraoperative EtCO2 following administration of intravenous Magnesium sulphate at 1min, 5min, 10min, 15min, 20min, 25min, 30min, 60min To evaluate the effect of magnesium sulphate on postoperative pain scores at 1min, 5min, 10min, 15min, 20min, 25min, 30min, 60min	—

Measure

Time frame

To assess the changes in intraoperative EtCO2 following administration of intravenous magnesium sulphate. To evaluate the effect of magnesium sulphate on postoperative pain scoresTimepoint: To assess the changes in intraoperative EtCO2 following administration of intravenous Magnesium sulphate at 1min, 5min, 10min, 15min, 20min, 25min, 30min, 60min To evaluate the effect of magnesium sulphate on postoperative pain scores at 1min, 5min, 10min, 15min, 20min, 25min, 30min, 60min

—

Secondary

Measure	Time frame
To assess the effect of intravenous magnesium sulphate on postoperative pain scores using the Visual Analog Scale (VAS) at 1,4,12 and 24 hours postoperatively. To observe any intraoperative hemodynamic changes (heart rate, mean arterial pressure) associated with magnesium sulphate administration. To record any adverse effects or complications related to magnesium sulphate administration Timepoint: To assess the effect of intravenous magnesium sulphate on postoperative pain scores using the Visual Analog Scale (VAS) at 1,4,12 and 24 hours postoperatively. To observe any intraoperative hemodynamic changes (heart rate, mean arterial pressure) associated with magnesium sulphate administration. To record any adverse effects or complications related to magnesium sulphate administration at baseline 1min 5min 10min 15min 20min 25min 30min	—

Measure

Time frame

To assess the effect of intravenous magnesium sulphate on postoperative pain scores using the Visual Analog Scale (VAS) at 1,4,12 and 24 hours postoperatively. To observe any intraoperative hemodynamic changes (heart rate, mean arterial pressure) associated with magnesium sulphate administration. To record any adverse effects or complications related to magnesium sulphate administration Timepoint: To assess the effect of intravenous magnesium sulphate on postoperative pain scores using the Visual Analog Scale (VAS) at 1,4,12 and 24 hours postoperatively. To observe any intraoperative hemodynamic changes (heart rate, mean arterial pressure) associated with magnesium sulphate administration. To record any adverse effects or complications related to magnesium sulphate administration at baseline 1min 5min 10min 15min 20min 25min 30min

—

Countries

India

Contacts

Public ContactDr Vijay Kumar

Pacific Medical College and Hospital

Chaharvijay03@gmail.com9413893218

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026